Search

Your search keyword '"Ring, Arne"' showing total 210 results
Start Over Author "Ring, Arne"
210 results on '"Ring, Arne"'

1. Statistik-Unterricht für Masterstudenten in Afrika – ein Erlebnisbericht mit Hintergründen

Author

Ring, Arne

Subjects
higher education, statistics, Africa, Computer applications to medicine. Medical informatics, R858-859.7, Infectious and parasitic diseases, RC109-216
Abstract

The AIMS (African Institute of Mathematical Sciences) supports the higher mathematical education of African Master students by providing postgraduate courses, which are taught by lecturers from both local and international institutes. This report reflects the author’s own experi; it aims to motivate lecturers to offer courses or supervision of research topics for AIMS students.

Published
2019
Full Text
View/download PDF

5. An efficient crossover design for thorough QT studies / Ein effizientes Crossover-Design für klinische Studien zur Untersuchung des QT-Intervalls

Author

Ring, Arne, Walter, Beate, Larbalestier, Anna, and Chanter, Dennis

Subjects
thorough QT study, Williams design, orthogonal Latin squares, statistical efficiency, permutations, group theory, Computer applications to medicine. Medical informatics, R858-859.7, Infectious and parasitic diseases, RC109-216
Abstract

Background: Thorough QT studies are typically a requirement of the clinical development program for new investigational drugs. These studies are a major cost factor in early development. The objectives of a typical thorough QT study (TQT) are to demonstrate (a) that therapeutic and supra-therapeutic doses of a new investigational drug do not prolong the ECG QT interval compared to placebo and (b) that an active control does show QT prolongation compared to placebo. In recent years, statistical research has led to substantial improvements in the design and analysis of these studies. We show one example of a recently developed, efficient study design. Methods: TQT studies conventionally follow a crossover design based on a Williams square of order four, as four treatments must be investigated. This design can be improved, since all comparisons in this design are active versus placebo. Hence it is efficient to double the number of placebo periods for each subject in order to reduce the sample size and the overall study costs. Several options for implementing this design are discussed and the preferred option is given. In addition, the corresponding changes in the analysis that are required to account for the multiple placebo periods are shown. Conclusions: Using a five period, four treatment design can lead to a reduction in the study costs of around 10%. Moreover, the number of active treatments administered is reduced which is a potential advantage for the investigation of drugs with a critical safety profile.

Published
2010

6. Group-by-treatment interaction effects in comparative bioavailability studies

Author

Universitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa, Universitat Politècnica de Catalunya. GRBIO - Grup de Recerca en Bioestadística i Bioinformàtica, Schütz, Helmut, Burger, Divan Aristo, Cobo Valeri, Erik, Dubins, David D., Farkás, Tibor, Labes, Detlew, Lang, Benjamin, Ocaña Rebull, Jordi, Ring, Arne, Shitova, Anastasia, Stus, Volodymyr, Tomashevskiy, Michael, Universitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa, Universitat Politècnica de Catalunya. GRBIO - Grup de Recerca en Bioestadística i Bioinformàtica, Schütz, Helmut, Burger, Divan Aristo, Cobo Valeri, Erik, Dubins, David D., Farkás, Tibor, Labes, Detlew, Lang, Benjamin, Ocaña Rebull, Jordi, Ring, Arne, Shitova, Anastasia, Stus, Volodymyr, and Tomashevskiy, Michael

Abstract

The version of record of this article, first published in AAPS journal, is available online at Publisher’s website: http://dx.doi.org/10.1208/s12248-024-00921-x, Comparative bioavailability studies often involve multiple groups of subjects for a variety of reasons, such as clinical capacity limitations. This raises questions about the validity of pooling data from these groups in the statistical analysis and whether a group-by-treatment interaction should be evaluated. We investigated the presence or absence of group-by-treatment interactions through both simulation techniques and a meta-study of well-controlled trials. Our findings reveal that the test falsely detects an interaction when no true group-by-treatment interaction exists. Conversely, when a true group-by-treatment interaction does exist, it often goes undetected. In our meta-study, the detected group-by-treatment interactions were observed at approximately the level of the test and, thus, can be considered false positives. Testing for a group-by-treatment interaction is both misleading and uninformative. It often falsely identifies an interaction when none exists and fails to detect a real one. This occurs because the test is performed between subjects in crossover designs, and studies are powered to compare treatments within subjects. This work demonstrates a lack of utility for including a group-by-treatment interaction in the model when assessing single-site comparative bioavailability studies, and the clinical trial study structure is divided into groups., Peer Reviewed, Postprint (published version)

Published
2024

7. State symmetries in matrices and vectors on finite state spaces

Author

Ring, Arne

Subjects
Mathematics - Rings and Algebras, 05E20, 15A03, 20G20
Abstract

State symmetries are defined as permutations which act on vector spaces of column vectors and square matrices, resulting in isotropy groups for specific vector spaces. A large number of properties for such objects is shown, to provide a rigorous basis for future applications. The main statement characterises the state symmetry of vector sequences $(v^{(i)})$ which are generated by powers of a generator matrix $M$: $v^{(i)}= M^i v^{(0)}$. A section of examples illustrates some applications of the theory., Comment: 35 pages, including a large number of examples

Published
2004

8. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

Author

Keenan, Joanne, Milton, Joanne, Doran, Zoe, Bray, Chris, Rouleau, Jean L, Collier, Jane, Pocock, Stuart, Standl, Eberhard, Swedberg, Karl, Weng, Jianping, Zhao, Dong, Petrie, Mark C, Connolly, Eugene, Jhund, Pardeep, MacDonald, Michael, Myles, Rachel C, Bai, Rong, Li, Jing, Liu, Zhaoping, Liu, Zhenyu, Peng, Dantao, Tong, Qiguang, Wang, Chunxue, Yan, Xiaowei, Zhang, Yuqing, Zhou, Jingmin, Sattar, Naveed, Fisher, Miles, Petrie, John R, Bethel, M Angelyn, Xu, Wen, Hearn, Sarah, Kappai, Anurag, Su, Shu-Yi, Liyanage, Winitha, Paul, Sanjoy, Pozzi, Emanuela, Ring, Arne, Athwal, Rajbir, Batra, Priyanka, Ferch, Andrea, Groves, Natasha, Kennedy, Irene, Nawalaniec, Olga, Patel, Yash, Roberts, Rachel, Rush, Victoria, Starrett, Jayne, Tang, Jennifer, Bi, Jing, Jiang, Zhe, Wei, Hua, Wei, Xiaoshuai, Zhang, Xuan, Yin, Jun, Sun, Yu, Hu, Rong, Liu, Yang, Long, Jianjing, Long, Yuefeng, Qiao, Guofang, Qiao, Haoyi, Sun, Xiaochun, Zhang, Yucheng, Zhou, Jing, Wang, Bangning, Chen, Bin, Deng, Lili, Han, Xiaoning, Hu, Taohong, Hua, Qi, Huo, Yanming, Li, Hongmei, Li, Hongwei, Liu, Lihua, Lu, Juming, Ma, Changsheng, Peng, Jianjun, Pi, Lin, Wang, Bin, Wei, Guanglin, Yang, Ming, Zhang, Shuyang, Zhang, Likun, Zhao, Xia, Zhou, Yujie, Shi, Libin, Wang, Mingsheng, Wu, Lirong, Han, Lei, Liao, Ronghong, Ran, Boli, She, Qiang, Tan, Jiancong, Xia, Mei, Yang, Chengming, Chen, Lianglong, Xiong, Shangquan, Yu, Ling, Pu, Xiaodong, Wang, Yan, Xie, Qiang, Chen, Cibin, Chen, Jiyan, Dong, Yugang, Wu, Zhaohui, Yuan, Yong, Zhou, Wanxing, Zhou, Shuxian, Chen, Xiaochao, Wu, Chun, Zhang, Aidong, Li, Zicheng, Lai, Shayi, Yang, Jin, Wei, Jinru, Kuang, Riyu, Zhao, Zilin, Zhong, Guoqiang, Cao, Xufen, Hao, Yuming, Liu, Gang, Wang, Dongmei, Fang, Hui, Kong, Lingjun, Li, Haitao, Wang, Changqing, Wang, Li'na, Li, Xueqi, Dong, Pingshuan, Zhang, Shouyan, Liu, Xincan, Zhao, Yulan, Liu, Hengliang, Gu, Ye, Liao, Yuhua, Su, Xi, Wang, Daowen, Wang, Hairong, Yang, Bo, Guo, Ying, Ouyang, Ding'an, Yang, Tianlun, Zhang, Yumin, Han, Yajun, Lin, Xuefeng, Zhao, Ruiping, Man, Ronghai, Bian, Rongwen, Biao, Xu, Hasimu, Buaijiaer, Jin, Hui, Liu, Ping, Yu, Jiangyi, Zhang, Hang, Xu, Chongli, Guo, Yan, Lv, Ke, Tao, Yijia, Xu, Xin, Yang, Zhenyu, Li, Dongye, Qi, Chunmei, Zhang, Guohui, Gu, Xiang, Hong, Lang, Hu, Ling, Li, Juxiang, Yang, Ping, Liu, Bin, Wang, Gang, Lin, Hailong, Liu, Jun, Zhang, Shuying, Han, Ping, Jin, Yuanzhe, Li, Ling, Li, Zhanquan, Luan, Hong, Song, Mei, Xue, Li, Hua, Yu, Liu, Dongwu, Yuan, Zuyi, Ye, Jixian, Gao, Feng, Feng, Jinhua, Wang, A'li, Ye, Shengming, Li, Xiaoyan, Su, Guohai, Zhang, Shufang, Hou, Zishan, Jiang, Wenbin, Zhou, Changyong, Wang, Yanping, Qi, Wenbo, Bao, Xiaomei, Feng, Bo, Gong, Hui, Gu, Shuiming, Gu, Mingjun, Guo, Xingui, He, Ben, Huang, Ying, Jiang, Jinfa, Jiang, Yifeng, Jin, Huigen, Li, Yuehua, Liu, Qiliang, Lu, Guoping, Miao, Peizhi, Qin, Yongwen, Wang, Yuanming, Wu, Shiyao, Xu, Yawei, Ma, Jin, Chen, Xiaoping, Liu, Xiumin, Tang, Jianing, Wang, Jingping, Tao, Jianhong, Zhang, Jun, Zhang, Tingjie, Li, Decai, Du, Xinping, Jiang, Tiemin, Lin, Jingna, Lu, Chengzhi, Ma, Hongjun, Gao, Bo, Guo, Xukun, Li, Tong, Zheng, Shaoxiong, Li, Zhongcheng, Zhao, Shuwu, Qiu, Qiang, Li, Kaili, Liu, Junming, Tang, Baopeng, Yuan, Zhanjun, Zhou, Jianhua, Bai, Wenwei, Guo, Tao, Zhang, Ge, Zhang, Hong, Hao, Yinglu, Fu, Guosheng, Tang, Lijiang, Chen, Jialun, Holman, Rury R, Coleman, Ruth L, Chan, Juliana C N, Chiasson, Jean-Louis, Feng, Huimei, Ge, Junbo, Gerstein, Hertzel C, Gray, Richard, Huo, Yong, Lang, Zhihui, McMurray, John J, Rydén, Lars, Schröder, Stefan, Sun, Yihong, Theodorakis, Michael J, Tendera, Michal, Tucker, Lynne, Tuomilehto, Jaakko, Wei, Yidong, Yang, Wenying, Wang, Duolao, Hu, Dayi, and Pan, Changyu

Published
2017
Full Text
View/download PDF

9. Infarct size following complete revascularization in patients presenting with STEMI: a comparison of immediate and staged in-hospital non-infarct related artery PCI subgroups in the CvLPRIT study

Author

Khan, Jamal N., Nazir, Sheraz A., Greenwood, John P., Dalby, Miles, Curzen, Nick, Hetherington, Simon, Kelly, Damian J., Blackman, Daniel, Ring, Arne, Peebles, Charles, Wong, Joyce, Sasikaran, Thiagarajah, Flather, Marcus, Swanton, Howard, Gershlick, Anthony H., and McCann, Gerry P.

Published
2016
Full Text
View/download PDF

19. Ibuprofen extrudate, a novel, rapidly dissolving ibuprofen formulation: relative bioavailability compared to ibuprofen lysinate and regular ibuprofen, and food effect on all formulations

Author

Klueglich, Matthias, Ring, Arne, Scheuerer, Stefan, Trommeshauser, Dirk, Schuijt, Chris, Liepold, Bernd, and Berndl, Gunther

Subjects
Ibuprofen -- Dosage and administration -- Complications and side effects, Rheumatic diseases -- Care and treatment -- Complications and side effects, Pain -- Care and treatment, Health, Care and treatment, Complications and side effects, Dosage and administration
Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, have been used for decades in the management of a multitude of pain conditions and rheumatic diseases. Their effects include inhibition of prostaglandin synthesis [...]

Published
2005

21. Evaluation of the drug‐drug interaction potential of treosulfan using a physiologically‐based pharmacokinetic modelling approach.

Author

Schaller, Stephan, Martins, Frederico S., Balazki, Pavel, Böhm, Sonja, Baumgart, Joachim, Hilger, Ralf A., Beelen, Dietrich W., Hemmelmann, Claudia, and Ring, Arne

Subjects
DRUG interactions, PHARMACOKINETICS, CYTOCHROME P-450, OMEPRAZOLE, CYTOCHROME P-450 CYP3A, ISOENZYMES
Abstract

Aims: The aim of this work is the development of a mechanistic physiologically‐based pharmacokinetic (PBPK) model using in vitro to in vivo extrapolation to conduct a drug‐drug interaction (DDI) assessment of treosulfan against two cytochrome p450 (CYP) isoenzymes and P‐glycoprotein (P‐gp) substrates. Methods: A PBPK model for treosulfan was developed de novo based on literature and unpublished clinical data. The PBPK DDI analysis was conducted using the U.S. Food and Drug Administration (FDA) DDI index drugs (probe substrates) midazolam, omeprazole and digoxin for CYP3A4, CYP2C19 and P‐gp, respectively. Qualified and documented PBPK models of the probe substrates have been adopted from an open‐source online model database. Results: The PBPK model for treosulfan, based on both in vitro and in vivo data, was able to predict the plasma concentration‐time profiles and exposure levels of treosulfan applied for a standard conditioning treatment. Medium and low potentials for DDI on CYP3A4 (maximum area under the concentration‐time curve ratio (AUCRmax = 2.23) and CYP2C19 (AUCRmax = 1.6) were predicted, respectively, using probe substrates midazolam and omeprazole. Treosulfan was not predicted to cause a DDI on P‐gp. Conclusion: Medicinal products with a narrow therapeutic index (eg, digoxin) that are substrates for CYP3A4, CYP2C19 or P‐gp should not be given during treatment with treosulfan. However, considering the comprehensive treosulfan‐based conditioning treatment schedule and the respective pharmacokinetic properties of the concomitantly used drugs (eg, half‐life), the potential for interaction on all evaluated mechanisms would be low (AUCR < 1.25), if concomitantly administered drugs are dosed either 2 hours before or 8 hours after the 2‐hour intravenous infusion of treosulfan. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. Additional file 1: of Infarct size following complete revascularization in patients presenting with STEMI: a comparison of immediate and staged in-hospital non-infarct related artery PCI subgroups in the CvLPRIT study

Author

Khan, Jamal, Sheraz Nazir, Greenwood, John, Dalby, Miles, Curzen, Nick, Hetherington, Simon, Kelly, Damian, Blackman, Daniel, Ring, Arne, Peebles, Charles, Wong, Joyce, Sasikaran, Thiagarajah, Flather, Marcus, Swanton, Howard, Gershlick, Anthony, and McCann, Gerry

Abstract

Supplemental data. Table S1. Patients with 2 or more â acuteâ MI. Table S2. CMR data excluding patients with chronic infarcts on the pre-discharge scan. Table S3. Discharge medication. Table S4. Clinical outcomes. (DOCX 80Â kb)

Published
2016
Full Text
View/download PDF

34. The randomised Complete versus Lesion-only PRimary percutaneous coronary Intervention Trial: Cardiovascular Magnetic Resonance imaging substudy (CvLPRIT-CMR)

Author

McCann, Gerry P., Khan, Jamal N., Greenwood, John P., Nazir, Sheraz A., Dalby, Miles, Curzen, Nick, Hetherington, Simon, Kelly, Damian J., Blackman, Daniel J., Ring, Arne, Peebles, Charles, Wong, Joyce, Sasikaran, Thiagarajah, Flather, Marcus, Swanton, Howard, and Gershlick, Anthony H.

Abstract

Background: Complete revascularisation in patients with multivessel disease who are treated with primary percutaneous coronary intervention (PPCI) may improve outcomes compared with an infarct-related artery (IRA)-only strategy. However, non-IRA percutaneous coronary intervention (PCI) may result in additional myocardial infarction (MI).Objectives: To determine whether or not in-hospital complete revascularisation was associated with increased total infarct size (IS) in patients participating in the Complete versus Lesion-only PPCI trial (CvLPRIT). Secondary objectives were to assess whether or not myocardial salvage index, myocardial ischaemia and final IS at follow-up were different with a complete revascularisation versus an IRA-only strategy.Design: Multicentre, prospective, randomised, controlled and open-label trial with blinded end-point analysis.Setting: Seven PPCI centres in England, UK.Participants: ST-segment elevation MI (STEMI) patients with multivessel disease (angiographic stenosis > 70% in one view or > 50% in orthogonal views) presenting within 12 hours of symptom onset and treated with the PPCI. Coronary artery bypass surgery, cardiogenic shock and contraindications to cardiovascular magnetic resonance (CMR; substudy only) imaging were exclusions.Interventions: Patients were randomised to either complete in-hospital revascularisation or an IRA-only strategy.Main outcome measures: The primary outcome was IS as measured by CMR undertaken at 48–72 hours post PPCI. Secondary outcome measures included microvascular obstruction, myocardial salvage index, left ventricular volumes and ejection fraction and final IS on the acute and follow-up CMR carried out at 9 months post STEMI.Results: Patients were recruited from May 2011 until May 2013 and followed up for 12 months. Of 296 patients randomised in the main CvLPRIT, 205 consented to participate in the CMR substudy and 203 had analysable images for the primary end point. Patients in the IRA-only group (n = 105) were well matched to those in the complete revascularisation group (n = 98) for all baseline characteristics {mean age 64.1 years [standard deviation (SD) 10.8 years] vs. 63.1 years (SD 11.3 years); male sex 89% vs. 79%, respectively}. Total IS was not significantly different in the IRA-only and complete revascularisation groups {median 13.5% [interquartile range (IQR) 6.2–21.9%] of left ventricular (LV) mass vs. median 12.6% (IQR 7.2–22.6%) LV mass, respectively; 95% confidence interval –4.09% to 31.17%; p = 0.57}. Myocardial salvage index was also not significantly different in the IRA-only and complete revascularisation groups [median 58.5% (IQR 32.8–74.9%) vs. median 60.5% (IQR 40.6–81.9%), respectively; p = 0.14]. The prevalence of non-IRA MI on acute CMR was higher in the complete revascularisation group than in the IRA-only group (22/98 vs. 11/105, respectively; p = 0.02). There was no difference in total IS, ischaemic burden or LV volumes between treatment groups at follow-up CMR.Limitations: The CMR substudy population may not be a true representation of the overall study population. The optimal timing of CMR to measure IS post PPCI is uncertain. Myocardial salvage was assessable in only 70% of patients.Conclusions: Multivessel PCI, compared with an IRA-only revascularisation, in the setting of STEMI led to a small increase in CMR imaging-detected non-IRA MI, but total IS was not increased.Future work: Larger studies are required to (1) confirm that death and MI are reduced by a complete revascularisation strategy; (2) assess whether or not functional assessment of non-IRA lesions results in similar outcomes to a pragmatic angiographic-based revascularisation strategy; and (3) assess the timing of in-hospital versus staged outpatient complete revascularisation.Trial registration: Current Controlled Trials ISRCTN70913605.Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. The main CvLPRIT was funded by the British Heart Foundation (SP/10/001) with support from the NIHR Comprehensive Local Research Networks.

Published
2016

36. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

Author

Holman, Rury R, primary, Coleman, Ruth L, additional, Chan, Juliana C N, additional, Chiasson, Jean-Louis, additional, Feng, Huimei, additional, Ge, Junbo, additional, Gerstein, Hertzel C, additional, Gray, Richard, additional, Huo, Yong, additional, Lang, Zhihui, additional, McMurray, John J, additional, Rydén, Lars, additional, Schröder, Stefan, additional, Sun, Yihong, additional, Theodorakis, Michael J, additional, Tendera, Michal, additional, Tucker, Lynne, additional, Tuomilehto, Jaakko, additional, Wei, Yidong, additional, Yang, Wenying, additional, Wang, Duolao, additional, Hu, Dayi, additional, Pan, Changyu, additional, Keenan, Joanne, additional, Milton, Joanne, additional, Doran, Zoe, additional, Bray, Chris, additional, Rouleau, Jean L, additional, Collier, Jane, additional, Pocock, Stuart, additional, Standl, Eberhard, additional, Swedberg, Karl, additional, Weng, Jianping, additional, Zhao, Dong, additional, Petrie, Mark C, additional, Connolly, Eugene, additional, Jhund, Pardeep, additional, MacDonald, Michael, additional, Myles, Rachel C, additional, Bai, Rong, additional, Li, Jing, additional, Liu, Zhaoping, additional, Liu, Zhenyu, additional, Peng, Dantao, additional, Tong, Qiguang, additional, Wang, Chunxue, additional, Yan, Xiaowei, additional, Zhang, Yuqing, additional, Zhou, Jingmin, additional, Sattar, Naveed, additional, Fisher, Miles, additional, Petrie, John R, additional, Bethel, M Angelyn, additional, Xu, Wen, additional, Hearn, Sarah, additional, Kappai, Anurag, additional, Su, Shu-Yi, additional, Liyanage, Winitha, additional, Paul, Sanjoy, additional, Pozzi, Emanuela, additional, Ring, Arne, additional, Athwal, Rajbir, additional, Batra, Priyanka, additional, Ferch, Andrea, additional, Groves, Natasha, additional, Kennedy, Irene, additional, Nawalaniec, Olga, additional, Patel, Yash, additional, Roberts, Rachel, additional, Rush, Victoria, additional, Starrett, Jayne, additional, Tang, Jennifer, additional, Bi, Jing, additional, Jiang, Zhe, additional, Wei, Hua, additional, Wei, Xiaoshuai, additional, Zhang, Xuan, additional, Yin, Jun, additional, Sun, Yu, additional, Hu, Rong, additional, Liu, Yang, additional, Long, Jianjing, additional, Long, Yuefeng, additional, Qiao, Guofang, additional, Qiao, Haoyi, additional, Sun, Xiaochun, additional, Zhang, Yucheng, additional, Zhou, Jing, additional, Wang, Bangning, additional, Chen, Bin, additional, Deng, Lili, additional, Han, Xiaoning, additional, Hu, Taohong, additional, Hua, Qi, additional, Huo, Yanming, additional, Li, Hongmei, additional, Li, Hongwei, additional, Liu, Lihua, additional, Lu, Juming, additional, Ma, Changsheng, additional, Peng, Jianjun, additional, Pi, Lin, additional, Wang, Bin, additional, Wei, Guanglin, additional, Yang, Ming, additional, Zhang, Shuyang, additional, Zhang, Likun, additional, Zhao, Xia, additional, Zhou, Yujie, additional, Shi, Libin, additional, Wang, Mingsheng, additional, Wu, Lirong, additional, Han, Lei, additional, Liao, Ronghong, additional, Ran, Boli, additional, She, Qiang, additional, Tan, Jiancong, additional, Xia, Mei, additional, Yang, Chengming, additional, Chen, Lianglong, additional, Xiong, Shangquan, additional, Yu, Ling, additional, Pu, Xiaodong, additional, Wang, Yan, additional, Xie, Qiang, additional, Chen, Cibin, additional, Chen, Jiyan, additional, Dong, Yugang, additional, Wu, Zhaohui, additional, Yuan, Yong, additional, Zhou, Wanxing, additional, Zhou, Shuxian, additional, Chen, Xiaochao, additional, Wu, Chun, additional, Zhang, Aidong, additional, Li, Zicheng, additional, Lai, Shayi, additional, Yang, Jin, additional, Wei, Jinru, additional, Kuang, Riyu, additional, Zhao, Zilin, additional, Zhong, Guoqiang, additional, Cao, Xufen, additional, Hao, Yuming, additional, Liu, Gang, additional, Wang, Dongmei, additional, Fang, Hui, additional, Kong, Lingjun, additional, Li, Haitao, additional, Wang, Changqing, additional, Wang, Li'na, additional, Li, Xueqi, additional, Dong, Pingshuan, additional, Zhang, Shouyan, additional, Liu, Xincan, additional, Zhao, Yulan, additional, Liu, Hengliang, additional, Gu, Ye, additional, Liao, Yuhua, additional, Su, Xi, additional, Wang, Daowen, additional, Wang, Hairong, additional, Yang, Bo, additional, Guo, Ying, additional, Ouyang, Ding'an, additional, Yang, Tianlun, additional, Zhang, Yumin, additional, Han, Yajun, additional, Lin, Xuefeng, additional, Zhao, Ruiping, additional, Man, Ronghai, additional, Bian, Rongwen, additional, Biao, Xu, additional, Hasimu, Buaijiaer, additional, Jin, Hui, additional, Liu, Ping, additional, Yu, Jiangyi, additional, Zhang, Hang, additional, Xu, Chongli, additional, Guo, Yan, additional, Lv, Ke, additional, Tao, Yijia, additional, Xu, Xin, additional, Yang, Zhenyu, additional, Li, Dongye, additional, Qi, Chunmei, additional, Zhang, Guohui, additional, Gu, Xiang, additional, Hong, Lang, additional, Hu, Ling, additional, Li, Juxiang, additional, Yang, Ping, additional, Liu, Bin, additional, Wang, Gang, additional, Lin, Hailong, additional, Liu, Jun, additional, Zhang, Shuying, additional, Han, Ping, additional, Jin, Yuanzhe, additional, Li, Ling, additional, Li, Zhanquan, additional, Luan, Hong, additional, Song, Mei, additional, Xue, Li, additional, Hua, Yu, additional, Liu, Dongwu, additional, Yuan, Zuyi, additional, Ye, Jixian, additional, Gao, Feng, additional, Feng, Jinhua, additional, Wang, A'li, additional, Ye, Shengming, additional, Li, Xiaoyan, additional, Su, Guohai, additional, Zhang, Shufang, additional, Hou, Zishan, additional, Jiang, Wenbin, additional, Zhou, Changyong, additional, Wang, Yanping, additional, Qi, Wenbo, additional, Bao, Xiaomei, additional, Feng, Bo, additional, Gong, Hui, additional, Gu, Shuiming, additional, Gu, Mingjun, additional, Guo, Xingui, additional, He, Ben, additional, Huang, Ying, additional, Jiang, Jinfa, additional, Jiang, Yifeng, additional, Jin, Huigen, additional, Li, Yuehua, additional, Liu, Qiliang, additional, Lu, Guoping, additional, Miao, Peizhi, additional, Qin, Yongwen, additional, Wang, Yuanming, additional, Wu, Shiyao, additional, Xu, Yawei, additional, Ma, Jin, additional, Chen, Xiaoping, additional, Liu, Xiumin, additional, Tang, Jianing, additional, Wang, Jingping, additional, Tao, Jianhong, additional, Zhang, Jun, additional, Zhang, Tingjie, additional, Li, Decai, additional, Du, Xinping, additional, Jiang, Tiemin, additional, Lin, Jingna, additional, Lu, Chengzhi, additional, Ma, Hongjun, additional, Gao, Bo, additional, Guo, Xukun, additional, Li, Tong, additional, Zheng, Shaoxiong, additional, Li, Zhongcheng, additional, Zhao, Shuwu, additional, Qiu, Qiang, additional, Li, Kaili, additional, Liu, Junming, additional, Tang, Baopeng, additional, Yuan, Zhanjun, additional, Zhou, Jianhua, additional, Bai, Wenwei, additional, Guo, Tao, additional, Zhang, Ge, additional, Zhang, Hong, additional, Hao, Yinglu, additional, Fu, Guosheng, additional, Tang, Lijiang, additional, and Chen, Jialun, additional

Published
2017
Full Text
View/download PDF

40. The randomised Complete versus Lesion-only PRimary percutaneous coronary Intervention Trial: Cardiovascular Magnetic Resonance imaging substudy (CvLPRIT-CMR)

Author

McCann, Gerry P, primary, Khan, Jamal N, additional, Greenwood, John P, additional, Nazir, Sheraz A, additional, Dalby, Miles, additional, Curzen, Nick, additional, Hetherington, Simon, additional, Kelly, Damian J, additional, Blackman, Daniel J, additional, Ring, Arne, additional, Peebles, Charles, additional, Wong, Joyce, additional, Sasikaran, Thiagarajah, additional, Flather, Marcus, additional, Swanton, Howard, additional, and Gershlick, Anthony H, additional

Published
2016
Full Text
View/download PDF

41. Statistical insights for scientific papers - a new UK initiative between science and press

Author

Ring, Arne, Givens, Naomi, Larbalestier, Anna, and Sheldon, Tom

Subjects
ddc: 610, Biometrische Beratung als Unterstützung der Berichterstattung in Tageszeitungen, 610 Medical sciences, Medicine
Abstract

The Science Media Centre (SMC) in the UK has initiated "Before the Headlines" [ref:1], a new service for busy science journalists who would like to report the results of a new scientific study in tomorrow’s newspaper. This initiative aims to improve the quality of science[for full text, please go to the a.m. URL], GMDS 2012; 57. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS)

Published
2012
Full Text
View/download PDF

42. To 'correct' or to 'adjust' for heart rate changes in the evaluation of QT interval prolongation

Author

Ring, Arne and Schall, Robert

Subjects
mixed models, ddc: 610, ECG, repeated measurements models, 610 Medical sciences, Medicine, Thorough QT study
Abstract

The assessment of QT prolongation in thorough QT (TQT) trials according to ICH E14 [ref:1] is often based on a two-step approach [ref:2]: Determination of the heart rate correction (e.g. slope between log(QT) and log(RR)) based on the data of this trial; Estimation of the [for full text, please go to the a.m. URL], Mainz//2011; 56. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (gmds), 6. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi)

Published
2011
Full Text
View/download PDF

43. Ein effizientes Crossover-Design für klinische Studien zur Untersuchung des QT-Intervalls

Author

Ring, Arne, Walter, Beate, Larbalestier, Anna, and Chanter, Dennis

Subjects
orthogonal Latin squares, statistical efficiency, statistische Effizienz, ddc: 610, permutations, Williams Design, group theory, Permutationen, 610 Medical sciences, Medicine, Gruppentheorie, thorough QT study, QT-Studie, orthogonale Lateinische Quadrate
Abstract

Background: Thorough QT studies are typically a requirement of the clinical development program for new investigational drugs. These studies are a major cost factor in early development. The objectives of a typical thorough QT study (TQT) are to demonstrate (a) that therapeutic and supra-therapeutic doses of a new investigational drug do not prolong the ECG QT interval compared to placebo and (b) that an active control does show QT prolongation compared to placebo. In recent years, statistical research has led to substantial improvements in the design and analysis of these studies. We show one example of a recently developed, efficient study design. Methods: TQT studies conventionally follow a crossover design based on a Williams square of order four, as four treatments must be investigated. This design can be improved, since all comparisons in this design are active versus placebo. Hence it is efficient to double the number of placebo periods for each subject in order to reduce the sample size and the overall study costs. Several options for implementing this design are discussed and the preferred option is given. In addition, the corresponding changes in the analysis that are required to account for the multiple placebo periods are shown. Conclusions: Using a five period, four treatment design can lead to a reduction in the study costs of around 10%. Moreover, the number of active treatments administered is reduced which is a potential advantage for the investigation of drugs with a critical safety profile., GMS Medizinische Informatik, Biometrie und Epidemiologie; 6(1):Doc05; ISSN 1860-9171

Published
2010

45. Complete Versus Lesion-Only Primary PCI

Author

McCann, Gerry P., primary, Khan, Jamal N., additional, Greenwood, John P., additional, Nazir, Sheraz, additional, Dalby, Miles, additional, Curzen, Nick, additional, Hetherington, Simon, additional, Kelly, Damian J., additional, Blackman, Daniel J., additional, Ring, Arne, additional, Peebles, Charles, additional, Wong, Joyce, additional, Sasikaran, Thiagarajah, additional, Flather, Marcus, additional, Swanton, Howard, additional, and Gershlick, Anthony H., additional

Published
2015
Full Text
View/download PDF

49. A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio®) in cardiac surgery: the REVAKI-1 study.

Author

Ring, Arne, Morris, Tom, Wozniak, Marcin, Sullo, Nikol, Dott, William, Verheyden, Veerle, Kumar, Tracy, Brunskill, Nigel, Vaja, Rakesh, and Murphy, Gavin J.

Subjects
*CARDIAC surgery, *SILDENAFIL, *CARDIOPULMONARY bypass, *PHARMACOKINETICS, *PHARMACODYNAMICS, *DOSE-effect relationship in pharmacology
Abstract

Aims Acute kidney injury (AKI) is a common and severe complication of cardiac surgery. There is no effective prevention or treatment. Sildenafil citrate (Revatio®, Pfizer Inc.), a phosphodiesterase type 5 inhibitor, prevents post cardiac surgery AKI in pre-clinical studies, however its use is contraindicated in patients with symptomatic cardiovascular disease. The aim of this study is to assess the safety and pharmacokinetics of intravenous sildenafil in cardiac surgery patients. Methods We conducted an open label, dose escalation study with six patients per dose level. The six doses were 2.5 mg, 5 mg or 10 mg as a bolus, either alone or followed by an additional 2 h infusion of 2.5 mg sildenafil. Results Thirty-six patients entered the trial, of which 33 completed it. The mean age was 69.9 years. One patient died during surgery, two others were removed from the trial before dosing (all at dose level 5 mg + 2.5 mg). The pharmacokinetic profile of sildenafil was similar to previously published studies. For a dose of 10 mg administered as a bolus followed by 2.5 mg administered over 2 h the results were AUC∞ 537 ng h ml−1, Cmax 189.4 ng ml−1 and t1/2 10.5 h. The drug was well tolerated with no serious adverse events related to drug administration. Higher sildenafil doses stabilized post-surgery nitric oxide bioavailability. Conclusions Pharmacokinetics of sildenafil during cardiopulmonary bypass were comparable to those of other patient groups. The drug was well tolerated at therapeutic plasma levels. These results support the further evaluation of sildenafil for the prevention of AKI in cardiac surgery. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results